CeMM

Research Center for Molecular Medicine of the Austrian Academy of Sciences At the center of CeMM’s interest are patients and associated diseases.

CeMM integrates basic research and clinical expertise to pursue innovative diagnostic and therapeutic approaches focused on cancer, inflammation and immune disorders.

23/06/2026

🎉 Big congratulations to CeMM PI Christoph Bock on receiving an ERC Advanced Grant from European Research Council!

What if CAR T cells could become stronger, smarter, and better at targeting solid tumors? In his new project, Solid-CART, Christoph and his team will combine CRISPR gene editing, single-cell technologies, and AI to develop the next generation of cancer immunotherapies.

🎥 Hear directly from Christoph about the vision behind the project, its potential impact, and what this prestigious grant will enable.

15/06/2026

🏳️‍🌈✨ Proud to have marched together once again at 2026!

Last Saturday, the CeMM community once again joined the vibrant Vienna Pride celebrations as part of the Rainbow Alliance for Life Sciences and Medicine 🌈🔬

Together with colleagues and friends from AITHYRA, Medizinische Universität Wien, and ÖH Med Wien, we took to the streets to celebrate diversity and stand for visibility, equality, and representation.

For us, groundbreaking science thrives in an inclusive environment. This is why we are committed to ensuring our institutes remain welcoming and empowering spaces for everyone.

A big thank you to the CeMM team and our partner institutes who share our values and walked alongside us! 🫶

📸 Take a look at the photo gallery by Franzi Kreis: https://bit.ly/4opcDEt

12/06/2026

🔬 Posters, pitches, keynote talks, feedback, creativity, and plenty of CeMM spirit!

Yesterday, our very first CeMM brought together the CeMM community for an afternoon of scientific exchange, thoughtful discussions, and a celebration of the high-quality research taking place across the institute. Our PhD students presented their projects, shared ideas, and received valuable feedback from postdocs and P*s, contributing to their scientific and professional development. It was a reminder that science is at its best when we learn and grow together!

A huge thank you to our postdoc representatives for bringing this initiative to life, and to everyone who presented, participated, and helped make this first PhD Day so special!

📸 Take a look at the photo gallery by Klaus Pichler: https://bit.ly/4vadpbc

12/06/2026

👩‍🔬👨🏾‍🔬 Bringing together expertise from across labs, at 𝗖𝗲𝗠𝗠'𝘀 𝗥𝗧 𝗥𝗲𝘁𝗿𝗲𝗮𝘁 on 10–11 June 2026 in Eisenstadt, our research technicians took the opportunity to exchange knowledge, discuss shared challenges, and strengthen connections.

From a workshop on creating clear and accessible protocols to conversational tables on topics such as lab organization, new project challenges, career development, self-advocacy, and time and stress management, participants learned from one another and shared experiences with colleagues from CeMM, St. Anna Kinderkrebsforschung, and AITHYRA.

A highlight was the session by Stephan Köstlbacher, Scientific Computing Specialist at AITHYRA, who shared insights into data management and how to embed artificial intelligence in biomedical research.

Organized by our dedicated RT representatives Ana A. González, Sabrina Lindinger, Lenka Novotná, Hannah Riegler, and Tatyana Stemmer, the retreat was a reminder of the essential role research technicians play in enabling scientific excellence at CeMM. A big thank you to the organizers and everyone who participated and made this gathering such a success! 👏

📸 Ana A. González / CeMM

10/06/2026

🚀 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗳𝗶𝗻𝗮𝗹 #𝗙𝗿𝗼𝗻𝘁𝗥𝗼𝘄𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗽𝗼𝘀𝘁 𝘄𝗶𝘁𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 #𝗖𝗲𝗠𝗠𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗥𝗲𝗽𝗼𝗿𝘁𝟮𝟬𝟮𝟱!

Last but not least, we shine a spotlight on the people behind the science: CeMM's Administration and Scientific Support teams!

At CeMM, research excellence relies on more than discoveries in the lab. An ever-evolving technical, operational, educational, financial, and ethical infrastructure, combined with the close collaboration between support and experimental teams, helps make innovation in molecular medicine possible.

In 2025, our teams supported initiatives ranging from organizing the first CeMM–AITHYRA Admin Retreat and the first CeMM-wide AI literacy workshop to strengthening PhD training, supporting successful grant applications, fostering entrepreneurship through the new Strategic Collaborative Program (SCP5), and launching CeMM's refreshed bilingual website.

Gathering in the 𝘍𝘦𝘴𝘵𝘪𝘷𝘦 𝘏𝘢𝘭𝘭 𝘰𝘧 𝘵𝘩𝘦 Österreichische Akademie der Wissenschaften, colleagues reflected on their individual strengths and the importance of connecting people and departments to foster collaboration, build trust, and successfully support the institute.

At CeMM, advancing medicine is a true team effort!

👉 https://bit.ly/4ecuLwP

📸 Klaus Pichler / CeMM

05/06/2026

🚀 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 #𝗙𝗿𝗼𝗻𝘁𝗥𝗼𝘄𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗽𝗼𝘀𝘁 𝘄𝗶𝘁𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 #𝗖𝗲𝗠𝗠𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗥𝗲𝗽𝗼𝗿𝘁𝟮𝟬𝟮𝟱!

Discover the CeMM facilities featured today:

🧫 The 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 (𝗠𝗗𝗣) combines proteomics, metabolomics, and chemical screening technologies to discover and characterize bioactive molecules.

In 2025, the platform implemented new proteomics workflows, upgraded metabolomics analysis workflows, and made full use of its recently upgraded chemical screening infrastructure, now providing access to more than 100,000 compounds and new “direct-to-biology” approaches for faster discovery.

👉 https://bit.ly/4x6sawY

📸 Team discussion at Das MuTh - Konzertsaal, Bühne & Programm (Klaus Pichler / CeMM)

🧬 As Austria’s first technology platform dedicated to next-generation sequencing (NGS) in biomedicine, the 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝘆 (𝗕𝗦𝗙) provides researchers with access to NGS expertise and supports projects from study design to sample preparation, sequencing, and bioinformatics analysis.

The team further expanded its single-cell portfolio, particularly for fixed cells, and adopted the latest GEM-X assays that generate data from twice as many cells as the previous generation, enabling more robust detection of rare cell populations.

👉 https://bit.ly/4dM4tCH

📸 Team discussion at the Vestibül of the Burgtheater (Klaus Pichler / CeMM)

03/06/2026

The call for the CeMM Starting PI positions with a research focus of Pain&Aging has been closed. We have received 100 applications from all over the world and thank all candidates for their interest, the time, and effort they put into the applications! It was a pleasure to meet some of the candidates in Vienna. 🙏 🫶

We wish all applicants success in their future endeavors, and hope you will follow CeMM in future and be interested in other opportunities, to visit, or to collaborate.

CeMM will soon open a new call for Adjunct Principal Investigator positions.

03/06/2026

𝗡𝗲𝘄 𝗹𝗮𝗯, 𝗻𝗲𝘄 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀! 💡

Our CeMM PhD student, Yee Kwan Law (Superti-Furga group), joined the EU-LIFE Connect Science 2026 program last week at the in Amsterdam 🇳🇱

As part of the exchange, he spent a week in Tassos Perrakis’ lab to explore new scientific perspectives in structural biology, discover cutting-edge facilities, connect with fellow researchers from across Europe, and also explore potential postdoctoral opportunities for the next stage of his career.

📹 Hear from Yee Kwan about his experience and how the program helped broaden his scientific horizons and build new connections.

26/05/2026

🚀 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 #𝗙𝗿𝗼𝗻𝘁𝗥𝗼𝘄𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗽𝗼𝘀𝘁 𝘄𝗶𝘁𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 #𝗖𝗲𝗠𝗠𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗥𝗲𝗽𝗼𝗿𝘁𝟮𝟬𝟮𝟱!

On the topic of clinical science, we feature today three CeMM research groups:

🧬 CeMM Adjunct PI Kaan Boztug’s group (St. Anna Kinderkrebsforschung / Universitätsklinikum Bonn) develops precision medicine approaches for childhood immune and hematological diseases.

In 2025, the team introduced an AI-supported precision medicine approach for pediatric acute myeloid leukemia (pedAML), a rare and highly aggressive blood cancer in children. This method helps predict treatment responses as soon as pedAML is diagnosed.

At the Theater in der Josefstadt, Boztug said: "There is little incentive for the pharmaceutical industry to invest in this area, because the chances of large revenues are smaller than for common diseases. This is something that academic medicine has to take care of."

👉 https://bit.ly/4tUUNKG

🩺 CeMM Adjunct PI Thomas Reiberger’s group (Medizinische Universität Wien) investigates novel treatment strategies for liver fibrosis and portal hypertension (PH), a dangerous consequence of liver disease that claims over 2 million lives globally each year.

In 2025, the team showed that lingering low-grade inflammation may prevent liver blood vessels from relaxing even after the underlying cause of liver disease is removed, highlighting inflammation as a promising therapeutic target.

At the Burgtheater, the group reflected on the translational impact of their work: “Most of us are physician scientists and we work with patients on a daily basis. The bench-to-bedside principle is something that we live every day,” said Reiberger.

👉 https://bit.ly/3Q43NPQ

🔬 Psoriasis is one of the most common chronic inflammatory skin diseases, affecting tens of millions of people worldwide. CeMM Adjunct PI Georg Stary’s group (Medizinische Universität Wien) studies tissue-resident immune cells in chronic inflammation, infection, and cancer.

Previous psoriasis treatment approaches focused on inhibiting pro-inflammatory immune cells, which can have the unintended side effect of increasing susceptibility to infection. In 2025, the team uncovered a new potential avenue for treating chronic skin inflammation, such as psoriasis and eczema.

During the group discussion at the 𝘌𝘳𝘰𝘪𝘤𝘢 𝘏𝘢𝘭𝘭 𝘢𝘵 𝘵𝘩𝘦 𝘗𝘢𝘭𝘢𝘪𝘴 𝘓𝘰𝘣𝘬𝘰𝘸𝘪𝘵𝘻 (Theatermuseum), Stary said: "Loss of the anti-inflammatory function of regulatory T cells is caused by a malfunction of the cellular metabolism." The researchers showed that restoring this function could offer a more specific approach to future therapies.

👉 https://bit.ly/4dGeik7

📸 Klaus Pichler / CeMM

21/05/2026

Congratulations to Miquel Muñoz Ordoño, from the group of CeMM Adjunct PI and AITHYRA Scientific Director LS Georg Winter, who successfully defended today his PhD thesis entitled "Bridging chemical biology and functional genomics: high-throughput mechanistic dissection of small molecule degraders".

During his PhD studies, he developed a novel drug discovery platform to find new molecular glue degraders in collaboration with the Erb lab at Scripps Research. After discovery, he then investigated their mechanism of action by performing loss-of-function screens to understand the molecular machinery employed by the degraders. Moreover, he applied other functional genomics approaches to identify the residues and domains in the involved proteins that are key for the degraders to function.

Your colleagues and friends at CeMM are proud of you, Miquel. Well done! 🎉👏

📸 Matthew Spencer / CeMM

Adresse

Lazarettgasse 14, AKH BT 25. 3
Wien
1090

Telefon

+43 1 40160 70011

Webseite

http://www.cemm.oeaw.ac.at/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CeMM erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.